Establishment and characterization of human laryngeal squamous cell carcinoma cell lines

Laryngoscope

Volumn 109, Issue 6, 1999, Pages 976-982

  Ku, Ja Lok ^a   Kim, Woo Ho ^a   Lee, Jae Ho ^a   Park, Hyun Sook ^a   Kim, Kwang Hyun ^a   Sung, Myung Whun ^a   Park, Jae Gahb ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Cell lines; Laryngeal squamous cell carcinoma; P16; P53; TGF RII

Indexed keywords

CISPLATIN; FLUOROURACIL; PHOSPHOTRANSFERASE; PROTEIN P15; PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL VIABILITY; DNA FINGERPRINTING; GENE ISOLATION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LARYNX CARCINOMA; MALE; MOLECULAR BIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DNA FINGERPRINTING; DNA PRIMERS; DNA, NEOPLASM; GENES, P16; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; LARYNGEAL NEOPLASMS; MICROSATELLITE REPEATS; MUTATION; POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0033040537     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199906000-00025     Document Type: Article

References (32)

1. Carey TE. Head and neck tumor cell lines. In: Hay RJ, Park JG, Gazdar A, eds. Atlas of Human Tumor Cell Lines. San Diego: Academic Press; 1994:79-120.
2. Brachman DG, Graves D, Yokes E, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992;52: 4832-4836.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancer. Science 1991;253:49-53.
4. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368: 753-756.
5. Orlow I, Lacombe L, Hannon GJ, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995;87:1524-1529.
6. Yoshida S, Todoroki T, Ichikawa Y, et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-2760.
7. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54:6353-6358.
8. Caldas C, Haha SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8: 27-32.
9. Myeroff LL, Parsons R, Kim SJ, et al. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-5547.
10. Park K, Kim SJ, Bang YJ, Park J-G, Kim NK, Roberts AB, Sporn MB. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci U S A 1994;91: 8772-8776.
11. Grenman R, Carey TE, McClatchey KD, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer 1991;67:2741-2747.
12. Carey TE, van Dyke DL, Worsham MJ, et al. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. Cancer Res 1989;49:6098-6107.
13. Park J-G, Lee JH, Kang MS, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 1995;62:276-282.
14. Ku JL, Kim WH, Park HS, Kang SB, Park J-G. Establishment and characterization of 12 uterine cervical-carcinoma cell lines: common sequence variation in the E7 gene of HPV-16-positive cell lines. Int J Cancer 1997;72:313-320.
15. Kang MS, Lee HJ, Ku JL, et al. Mutation of p53 gene in hepatocellular-carcinoma cell lines with HBX DNA. Int J Cancer 1996;67:898-902.
16. Williamson MP, Elder PA, Shaw ME, Devlin, Knowles MA. p16(CDKN2) is a major deletion target at 9p21 in bladder cancer. Human Mol Genet 1995;4:1569-1577.
17. Han HJ, Maruyama M, Baba S, Park JG, Nakamura Y. Genomic structure of human mismatch repair gene, hMLH1, and its mutation analysis in patients with hereditary non-polyposis colorectal cancer. Human Mol Genet 1995;4:237-242.
18. Lu SL, Zhang WC, Akiyama Y, Nomizu T, Yuasa Y. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res 1996;56:4595-4598.
19. Capon DJ, Seeburg PH, McGrath JP, Hayflick JS, Edman U, Levinson AD, Goeddel DV. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 1983;304:507-513.
20. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:321-326.
21. Zhang SY, Klein-Szanto AJ, Sauter ER, et al. Higher frequency of alteration in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994;54:5050-5053.
22. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3633.
23. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-4530.
24. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102.
25. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 1995;55: 5548-5550.
26. Munoz-Antonia T, Li X, Reiss M, Jackson R, Antonia S. A mutation in the transforming growth factor type II receptor gene promoter associated with loss of gene expression. Cancer Res 1996;56:4831-4935.
27. De Jonge RR, Garrigue-Antar L, Vellucci VF, Reiss M. Frequent inactivation of the transforming growth factor β type II receptor in small-cell lung carcinoma cells. Oncology Res 1997;9:89-98.
28. Savage C, Das P, Finelli A, Townsend SR, Sun C-Y, Baird SE, Padgett RW. Caenorhabditis elegans genes sma-2, sma-3, sma-3 and sma-4 define a conserved family of transforming growth factor β pathway components. Proc Natl Acad Sci USA 1996;93:790-794.
29. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J-I, Kawabata M, Miyazono K. Smad6 inhibits signalling by the TGF-β superfamily. Nature 1997;389:622-626.
30. Nakao A, Afrakhte M, Moren A, et al. Identification of SmadY, a TGFβ-inducible antagonist of TGF-β signalling. Nature 1997;389:631-635.
31. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995;55: 3982-3987.
32. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGF-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-552.